Fueled by LabCorp partnership, Circuit Clinical eyes major expansion
By Dan Miner
Buffalo Business First
For the last five years, Circuit Clinical has been a testing ground for the ideals of Irfan Khan, a cardiologist-turned-startup founder.
This has been a year of maturation for the Buffalo biotech company, which seeks to make experimental trials more accessible to patients.
Circuit Clinical started the year by providing access to clinical trials to a network of doctors in Western New York who would offer trials to their patients. That has now expanded into the eastern parts of New York state and New Jersey, with an eye on a much bigger footprint in 2021.
Circuit Clinical is partnering with clinical laboratory giant LabCorp to help expand. The company’s clinical trial portfolio this year has included diagnostic tests and treatments for Covid-19. Khan said it is likely Circuit Clinical will participate in coronavirus vaccine clinical trials at some point.
“We are seen nationally as innovators and as a company with ideas that can scale,” Khan said. “We’re looking ahead to a very high-growth and ambitious year.”
Circuit Clinical won a $500,000 award last year in the 43North competition, and came into 2020 with about 20 employees. Now there are 28. The company closed on $2.2 million in funding earlier this year from local investment groups.
The startup also offers its TrialScout software platform, a tool to engage patients who are researching or going through experimental drug therapies.
Khan said the hires this year of Deena Bernstein, senior vice president of network and partnerships, and Michael Schooley, senior vice president of business development, were key to polishing the business model and opening new markets.
“This year has been about putting the right executives in place to tell the story of how Circuit Clinical can effectively scale,” Khan said. “We have big announcements coming that will make it clear we are in high growth mode.”
This article originally appeared in Buffalo Business First.